Phase 2 N=54 Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA)
Lymphedema
Primary: Change in Skin Thickness of the Calf of the Most Affected Leg, Measured by Skinfold Calipers — -6.83; -7.75 mm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=245 A Randomized Controlled Trial of an Antiretroviral Treatment Adherence Intervention for HIV+ African Americans
HIV/AIDS
Primary: Continuous Adherence — 68.80; 70.95; 72.76; 70.02 percentage of doses taken — p=.08
Phase 2 N=447 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
Cystic Fibrosis
Primary: Pulmonary Exacerbation (PEx) Rate Over 28 Weeks — 0.911; 0.749; 0.842 events per participant/28 weeks
Phase 2 N=33 A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection
Hepatitis D, Chronic
Primary: Change From Baseline in HDV Viral Load. — -2.14; -1.16 Change in HDV RNA log IU/mL
Phase 2 N=123 Open-label Extension to Protocol 1042-0600
Epilepsies, Partial
Primary: Percent Change From Baseline in Weekly Seizure Frequency During Weeks 1 Through 117 — -14.8; -12.3; -14.0; -13.7 Percent Change
N/A N=34 Total Shoulder Arthroplasty Near-infrared Spectroscopy
Cerebral Ischemia
Primary: Number of Cerebral Desaturation Events — 0 Number of CDE Incidences
Phase 3 N=255 To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
HER2-ve Metastatic Breast Cancer · Germline BRCA1/2 Mutations · Somatic BRCA1/2 Mutations
Primary: Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants — 8.18 months
Phase 3 N=174 Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis
Myasthenia Gravis, Generalized
Primary: Change From Baseline (CFB) to Week 12 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score — -2.30; -4.39 score on a scale — p=<0.001
Phase 2 N=140 Trial of AD036 in Obstructive Sleep Apnea
Obstructive Sleep Apnea
Primary: Apnea Hypopnea Index (AHI) — 3; 2; 6; 8 Participants
Phase 1 N=15 Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition
Pancreas Cancer · Pancreatic Cancer · Cancer of the Pancreas
Primary: Tolerability as Measured by Number of Participants With Related Adverse Events — 15; 1; 1; 1 Participants
N/A N=174 RESCUE Stroke Caregiver Website to Enhance Discharge Planning
Depression · Quality of Life · Self Efficacy
Primary: Change in Depressive Symptoms at 11 Weeks — -1.8; -1.6 score on a scale — p=0.693
N/A N=316 PACCT: Partnering Around Cancer Clinical Trials
Prostate Cancer
Primary: Physician Offers of a Clinical Trial — 14 Participants
N/A N=336 Assessment of Myocardial Ischemic-Reperfusion Injury During Off- and On- Pump CABG
Ischemic Heart Disease · Coronary Artery Disease · Ischemic Reperfusion Injury
Primary: Myeloperoxidase — 184.3; 66.5; 144.71 g/L
N/A N=18 Adaptation of a Digital Weight Loss Intervention Promoting Self-regulation for Use in Type 2 Diabetes
Diabetes Mellitus, Type 2 · Overweight and Obesity
Primary: Change in Weight — -4.54 kg
Phase 3 N=547 Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
Active Systemic Lupus Erythematosus
Primary: Exposure-adjusted Incidence Rates (EAIRs) of Adverse Events of Special Interest (AESIs) — 11.0; 9.6; 12.9; 12.5 Events per 100 participant years